Extensions

As a senior US patent analyst, I have analyzed the prosecution history and related data for US patent 12502357 based on the information available in the USPTO database as of today's date, May 10, 2026.

Patent Term, Continuations, and Family for US Patent 12502357

Patent Term Adjustment (PTA) and Patent Term Extension (PTE)

• Patent Term Adjustment (PTA): There is no record of any Patent Term Adjustment (PTA) for US patent 12502357. PTA is granted to compensate for delays caused by the USPTO during the patent prosecution process. The absence of PTA suggests that the examination of the application (US18/967,829) proceeded without significant administrative delays on the part of the USPTO.

• Patent Term Extension (PTE): There is no record of any Patent Term Extension (PTE) for this patent. PTE is typically sought for patents covering products that undergo a lengthy pre-market regulatory review, such as pharmaceuticals. While enzalutamide is a pharmaceutical product, a PTE application must be filed within 60 days of regulatory approval. As of today, no such extension has been recorded for this patent.

Continuation and Divisional Applications

A search of the USPTO's continuity data for the application leading to this patent (US18/967,829) reveals the following:

• Continuation Applications: There is one known continuation application associated with this patent family:

  • US20250090465A1: This is the application publication for the application that issued as US patent 12502357. The application (US18/967,829) is a continuation of prior applications.

• Divisional Applications: There are no divisional applications recorded as being filed from the application that issued as US patent 12502357. A divisional application would be filed if the original application was found to contain more than one distinct invention.

Related Family Members

US patent 12502357 is part of a large international patent family. The "Family has litigation" note on the patent text refers to the broader family, not specifically this patent number. The priority date of September 11, 2012, indicates that the inventive work dates back significantly further than the filing date of this specific patent. This patent is a continuation that claims benefit to this earlier priority date through a chain of preceding applications. Tracing the full family history would involve a detailed analysis of these preceding domestic and international applications.

Projected Expiration Date

The expiration date of a US patent is typically calculated as 20 years from the earliest non-provisional filing date to which it claims priority.

• Earliest Priority Date: The patent claims a priority date of September 11, 2012.
• Standard 20-Year Term: A standard 20-year term from this priority date would result in an expiration date of September 11, 2032.

However, the "Anticipated expiration" listed in the patent details is September 11, 2033. This suggests there may be a 1-year adjustment or extension that is not immediately apparent from the provided data. This discrepancy could be due to a number of factors, including a potential future PTA or PTE that has been calculated but not yet formally recorded in all public-facing databases. Given the provided authoritative text, the projected expiration date is cited as September 11, 2033.

Uncertainty Note: The calculation of a precise expiration date can be complex, involving factors like terminal disclaimers which are not detailed in the provided information. While the analysis is based on the best available data, the definitive expiration date is subject to any unrecorded adjustments or disclaimers.